Botulinus Toxin, Tetanus Toxin, and Anthrax Lethal Factor Inhibitors

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 705-720

  Mastrolorenzo, Antonio ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Botulinus toxin, tetanus toxin and anthrax lethal factor inhibitors; Inhibitors of BoNT and TeNT zinc proteases; Tetanus and botulinum neurotoxins Clostridium tetani and Clostridium botulinum

Indexed keywords

EID: 79958185412     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch29     Document Type: Chapter

References (42)

1. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80, 717-766.
2. Humeau,Y.; Doussau, F.; Grant, N. J.; Poulain, B. Howbotulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82, 427-446.
3. Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B. R.;Montecucco, C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359, 832-834.
4. Schiavo, G.; Rossetto, O.; Catsicas, S.; Polverino de Laureto, P.; DasGupta, B. R.; Benfenati, F.; Montecucco, C. Identification of the nerve terminal targets of botulinum neurotoxins serotypes A, D and E. J. Biol. Chem. 1993, 268, 23784-23787.
5. Lacy, D. B.; Tepp, W.; Cohen, A. C.; DasGupta, B. R.; Stevens, R. C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5, 898-902.
6. Swaminathan, S.; Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7, 617-619.
7. Arndt, J.W.; Yu, W.; Bi, F.; Stevens, R. C. Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate, recognition. Biochemistry 2005, 44, 9574-9580.
8. Arndt, J.W.; Chai, Q.; Christian, T.; Stevens, R. C. Structure of botulinum neurotoxin type D light chain at 1.65Åresolution: repercussions for VAMP-2 substrate specificity. Biochemistry 2006, 45, 3255-3262.
9. Hanson, M. A.; Stevens, R. C. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0Åresolution. Nat. Struct. Biol. 2000, 7, 687-692.
10. Agarwal, R.; Eswaramoorthy, S.; Kumaran, D.; Binz, T.; Swaminathan, S. Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212!Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry 2004, 43, 6637-6644.
11. Chen, S.;Hall, C.; Barbieri, J. T. Substrate recognition ofVAMP-2 by botulinumneurotoxin B and tetanus neurotoxin. J. Biol. Chem. 2008, 283, 21153-21159.
12. Rao, K. N.; Kumaran, D.; Binz, T.; Swaminathan, S. Structural analysis of the catalytic domain of tetanus neurotoxin. Toxicon 2005, 45, 929-939.
13. Martin, L.; Cornille, F.; Coric, P.; Roques, B. P.; Fournié-Zaluski, M. C. b-Amino-thiols inhibit the zinc metallopeptidase activity of tetanus toxin light chain. J. Med. Chem. 1998, 41, 3450-3460.
14. Martin, L.; Cornille, F.; Turcaud, S.; Meudal, H.; Roques, B. P.; Fournié-Zaluski, M. C. Metallopeptidase inhibitors of tetanus toxin: a combinatorial approach. J. Med. Chem. 1999, 49, 515-525.
15. Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 2008, 7, 168-181.
16. Burnett, J. C.; Schmidt, J. J.; Stafford, R. G.; Panchal, R. G.; Nguyen, T. L.; Hermone, A. R.;Vennerstrom, J. L.; McGrath, C. F.; Lane, D. J.; Sausville, E. A.; Zaharevitz, D.W.; Gussio, R.; Bavari, S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem. Biophys. Res. Commun. 2003, 310, 84-93.
17. Burnett, J. C.; Opsenica, D.; Sriraghavan, K.; Panchal, R. G.; Ruthel, G.; Hermone, A. R.; Nguyen, T. L.; Kenny, T. A.; Lane, D. J.; McGrath, C. F.; Schmidt, J. J.; Vennerstrom, J. L.; Gussio, R.; Solaja, B. A.; Bavari, S. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J. Med. Chem. 2007, 50, 2127-2136.
18. Elliott, J. L.; Mogridge, J.; Collier, R. J. A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Biochemistry 2000, 39, 6706-6713.
19. Leppla, S. H. Anthrax toxin lethal factor. In Handbook of Proteolytic Enzymes (CD-ROM); Barrett, A. J.; Rawlings, N. D.; Woessner, J. F. Jr.,Eds.; Academic Press: London, 1998; Chapter 511.
20. Duesbery, N. S.; Webb, C. P.; Leppla, S. H.; Gordon, V. M.; Klimpel, K. R.; Copeland, T. D.; Ahn, N. G.; Oskarsson, M. K.; Fukasawa, K.; Paull, K. D.; Vande Woude, G. F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280, 734-737.
21. Vitale, G.; Pellizzari, R.; Recchi, C.; Napolitani, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 1998, 248, 706-711.
22. Pellizzari, R.; Guidi-Rontani, C.; Vitale, G.; Mock, M.; Montecucco, C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNF-alpha. FEBS Lett. 1999, 462, 199-204.
23. Menard, A.; Papini, E.; Mock, M.; Montecucco, C. The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors. Biochem. J. 1996, 320, 687-691.
24. Pannifer,A. D.;Wong, T.Y.; Schwarzenbacher, R.; Renatus, M.; Petosa, C.; Bienkowska, J.; Lacy, D. B.; Collier, R. J.; Park, S.; Leppla, S. H.; Hanna, P.; Liddington, R. C. Crystal structure of the anthrax lethal factor. Nature 2001, 414, 160-161.
25. Tonello, F.; Naletto, L.; Romanello, V.; Dal Molin, F.; Montecucco, C. Tyrosine-728 and glutamic acid-735 are essential for the metalloproteolytic activity of the lethal factor of Bacillus anthracis. Biochem. Biophys. Res. Commun. 2004, 313, 496-502.
26. De Simone, G.; Menchise, V.; Omaggio, S.; Pedone, C.; Scozzafava, A.; Supuran, C. T. Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: Molecular and X-ray crystallographic studies. Biochemistry 2003, 42, 9013-9021.
27. Turk, B. E. Discovery and development of anthrax lethal factor metalloproteinase inhibitors. Curr. Pharm. Biotechnol. 2008, 9, 24-33.
28. Gowravaram, M. R.; Tomczuk, B. E.; Johnson, J. S.; Delecki, D.; Cook, E. R.; Ghose, A. K.; Mathiowetz, A. M.; Spurlino, J. C.; Rubin, B.; Smith, D. L.; Pulvino, T.; Wahl, R. C. Inhibition of matrix metalloproteinases by hydroxamates containing heteroatombased modifications of the P10 group. J. Med. Chem. 1995, 38, 2570-2581.
29. Shoop,W. L.; Xiong, Y.;Wiltsie, J.;Woods, A.; Guo, J.; Pivnichny, J. V.; Felcetto, T.; Michael, B. F.; Bansal, A.; Cummings, R. T.; Cunningham, B. R.; Friedlander, A. M.; Douglas, C.M.; Patel, S. B.;Wisniewski, D.; Scapin, G.; Salowe, S. P.; Zaller, D. M.; Chapman, K. T.; Scolnick, E. M.; Schmatz, D. M.; Bartizal, K.; MacCoss, M.; Hermes, J. D. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. USA. 2005, 102, 7958-7963.
30. Xiong, Y.; Wiltsie, J.; Woods, A.; Guo, J.; Pivnichny, J. V.; Tang, W.; Bansal, A.; Cummings, R. T.; Cunningham, B. R.; Friedlander, A. M.; Douglas, C. M.; Salowe, S. P.; Zaller, D. M.; Scolnick, E. M.; Schmatz, D. M.; Bartizal, K.; Hermes, J. D.; MacCoss, M.; Chapman, K. T. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg. Med. Chem. Lett. 2006, 16, 964-968.
31. Johnson, S. L.; Jung, D.; Forino, M.; Chen, Y.; Satterthwait, A.; Rozanov, D.V.; Strongin, A. Y.; Pellecchia, M. Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. J. Med. Chem. 2006, 49, 27-30.
32. Min, D. H.; Tang, W. J.; Mrksich, M. Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. Nat. Biotechnol. 2004, 22, 717-723.
33. Soelaiman, S.;Wei, B. Q.; Bergson, P.; Lee, Y. S.; Shen, Y.; Mrksich, M.; Shoichet, B. K.; Tang, W. J. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 2003, 278, 25990-25997.
34. Scott, A. B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980, 87, 1044-1049.
35. Huang, W.; Foster, J. A.; Rogachefsky, A. S. Pharmacology of botulinum toxin. J. Am. Acad. Dermatol. 2000, 43, 249-259.
36. Solomon, B. A.; Hayman, R. Botulinum toxin type A for palmar and digital hyperhidrosis. J. Am. Acad. Dermatol. 2000, 42, 1026-1029.
37. Eapen, B. R. Molecular biology of botulinum neurotoxin serotype A: a cosmetic perspective. J. Cosmet. Dermatol. 2008, 7, 221-225.
38. Schulte-Mattler, W. J. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs 2008, 22, 725-738.
39. Laing, T. A.; Laing, M. E.; O'Sullivan, S. T. Botulinum toxin for treatment of glandular hypersecretory disorders. J. Plast. Reconstr. Aesthet. Surg. 2008, 61, 1024-1028.
40. Jabbari, B. Botulinum neurotoxins in the treatment of refractory pain. Nat. Clin. Pract. Neurol. 2008, 4, 676-685.
41. Eccleston, K. J.;Woolley, P.D. Botulinum toxin for urogenital conditions. Int. J. STDAIDS 2008, 19, 797-799.
42. De Ridder,D. Botulinum toxin: future developments. BJU Int. 2008, 102 (Suppl. 1), 20-22.